- Home
- ALKS
ALKS
Alkermes plc
as 02-21-2025 4:00pm EST
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
| Founded: | 1987 | Country: | Ireland |
| Employees: | N/A | City: | DUBLIN 4 |
| Market Cap: | 5.7B | IPO Year: | 1991 |
| Target Price: | $37.25 | AVG Volume (30 days): | 1.9M |
| Analyst Decision: | Buy | Number of Analysts: | 12 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 2.17 | EPS Growth: | 3.47 |
| 52 Week Low/High: | $22.90 - $36.45 | Next Earning Date: | 02-12-2025 |
| Revenue: | $1,557,632,000 | Revenue Growth: | -6.36% |
| Revenue Growth (this year): | -7.94% | Revenue Growth (next year): | 4.67% |
Stock Insider Trading Activity of Alkermes plc (ALKS)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Parisi Samuel Joseph | ALKS | VP, Finance (Interim PAO) | Feb 18 '25 | Sell | $35.69 | 1,327 | $47,360.63 | 7,717 | |
| Hopkinson Craig C. | ALKS | EVP R&D, Chief Medical Officer | Jan 30 '25 | Sell | $32.05 | 100,918 | $3,234,381.53 | 44,290 | |
| Hopkinson Craig C. | ALKS | EVP R&D, Chief Medical Officer | Dec 9 '24 | Sell | $32.07 | 61,151 | $1,961,406.09 | 44,290 | |
| LAURENCIN CATO T | ALKS | Director | Dec 8 '24 | Sell | $31.85 | 2,691 | $85,708.35 | 23,013 | |
| Hopkinson Craig C. | ALKS | EVP R&D, Chief Medical Officer | Dec 5 '24 | Sell | $31.50 | 9,221 | $290,461.50 | 44,290 | |
| Hopkinson Craig C. | ALKS | EVP R&D, Chief Medical Officer | Dec 4 '24 | Sell | $30.77 | 14,349 | $441,550.30 | 44,290 | |
| Nichols Christian Todd | ALKS | SVP, Chief Commercial Officer | Nov 27 '24 | Sell | $29.15 | 5,208 | $151,813.20 | 60,703 |
Latest Alkermes plc News
ALKS Breaking Stock News: Dive into ALKS Ticker-Specific Updates for Smart Investing
Simply Wall St.
7 days ago
Alkermes plc Just Beat EPS By 12%: Here's What Analysts Think Will Happen Next
Zacks
9 days ago
Alkermes' Q4 Earnings & Revenues Surpass Estimates, Stock Up
Simply Wall St.
9 days ago
Alkermes Full Year 2024 Earnings: Beats Expectations
GuruFocus.com
9 days ago
Alkermes PLC (ALKS) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Debt-Free Milestone
Zacks
10 days ago
Alkermes (ALKS) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
MT Newswires
10 days ago
Sector Update: Health Care Stocks Lean Lower Pre-Bell Wednesday
Zacks
10 days ago
Alkermes (ALKS) Q4 Earnings and Revenues Surpass Estimates
Associated Press Finance
10 days ago
Alkermes: Q4 Earnings Snapshot
Compare ALKS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ALKS Alkermes plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.